PULMONARY LESIONS ASSOCIATED WITH BLEOMYCIN THERAPY IN MALIGNANCIES

Area of Science:

• Pulmonary Pathology
• Oncology
• Toxicology

Background:

• Bleomycin is a chemotherapy agent used to treat various cancers.
• Drug-induced lung injury is a significant concern in cancer patients undergoing treatment.
• Understanding the specific pulmonary manifestations of bleomycin is crucial for patient management.

Purpose of the Study:

• To investigate the autopsy findings of pulmonary lesions in patients treated with bleomycin.
• To characterize the histological changes and distribution of these lesions.
• To correlate clinical symptoms with pathological findings.

Main Methods:

• Autopsy examination of seven patients with malignancy treated with bleomycin.
• Histopathological analysis of lung tissue.
• Correlation of findings with clinical data, including respiratory distress.

Main Results:

• Pulmonary lesions were observed in all studied patients, with a predilection for lower lobes and subpleural areas.
• All cases showed diffuse alveolar damage progressing to interstitial pneumonitis.
• Histological changes included proteinaceous exudate, interstitial fibrosis, and epithelial dysplasia resembling metastatic nodules.

Conclusions:

• Bleomycin treatment is associated with significant pulmonary toxicity.
• The observed lung lesions can present with respiratory distress and mimic metastatic disease.
• These findings highlight the importance of monitoring pulmonary function in patients receiving bleomycin.